Targeted delivery of levofloxacin-liposomes for the treatment of pulmonary inflammation

The present study systematically studied the intravenous injectable formulation of liposomes loaded with levofloxacin, an amphipathic antibiotic. The aim of the present study was to design passive targeting liposomes, which might improve the antibacterial activity by accumulating in lung and reduce side effects such as neurotoxicity and hematotoxicity associated with direct injection of the drug. Levofloxacin-loaded liposomes were prepared by the ammonium sulfate gradients method. The formulated liposomes were found to be relatively uniform in size (7.424 ± 0.689 μm) with a positive zeta potential (+13.11 ± 1.08 mV). The entrapment efficiency of levofloxacin-loaded liposomes ranged from 82.19% to 86.23%. The administered liposomes were composed of soybean phosphatides, cholesterol, levofloxacin, and sulfate which existed in inner liposomes. In vitro drug release was monitored for up to 3 days, and the release behavior was in accordance with the Weibull equation. The levofloxacin-loaded liposomes exhibited a longer elimination half-life (t1/2β) in vivo compared with the levofloxacin solution after intravenous injection to New Zealand rabbits. The encapsulation of levofloxacin in liposomes also changed its biodistribution in mice after intravenous injection in caudal vein. Liposomal levofloxacin performed significant lung targeting efficiency with area under the concentration–time curve, targeting efficacy (Te), and The intake rate (Re) of lung, all showing obvious increase. In addition, liposomal formulations presented accumulative activity in spleen and liver. Conversely, the biodistribution of liposomal formulation in non-RES sites, such as kidney, brain, heart, and plasma, decreased with descending peak concentration ration (Ce) compared to levofloxacin injection, which potentially resulted in the reduction of the side effects of free drug. These results indicated that the levofloxacin-loaded liposomes were promising passive targeting to lung for pulmonary infection treatment.

[1]  M. Fresta,et al.  Formulation parameters of fluoroquinolone-loaded liposomes and in vitro antimicrobial activity☆ , 1995 .

[2]  A. Bayer,et al.  Characterization of mechanisms of quinolone resistance in Pseudomonas aeruginosa strains isolated in vitro and in vivo during experimental endocarditis , 1989, Antimicrobial Agents and Chemotherapy.

[3]  D. Andreu,et al.  Studies on the antimicrobial activity of cecropin A-melittin hybrid peptides in colistin-resistant clinical isolates of Acinetobacter baumannii. , 2006, The Journal of antimicrobial chemotherapy.

[4]  M. Fresta,et al.  Intracellular accumulation of ofloxacin-loaded liposomes in human synovial fibroblasts , 1995, Antimicrobial agents and chemotherapy.

[5]  J. Li,et al.  Heteroresistance to Colistin in Multidrug-Resistant Acinetobacter baumannii , 2006, Antimicrobial Agents and Chemotherapy.

[6]  M. Glavas-Dodov,et al.  The effects of lyophilization on the stability of liposomes containing 5-FU. , 2005, International journal of pharmaceutics.

[7]  I-Ming Chu,et al.  Effect of composition on the stability of liposomal irinotecan prepared by a pH gradient method. , 2003, Journal of bioscience and bioengineering.

[8]  Sanyog Jain,et al.  Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages. , 2004, International journal of pharmaceutics.

[9]  Y. Barenholz,et al.  Ammonium Sulfate Gradients for Efficient and Stable Remote Loading of Amphipathic Weak Bases into Liposomes and Ligandoliposomes. , 1994 .

[10]  N. Zhang,et al.  Pharmacokinetics and targeting property of TFu-loaded liposomes with different sizes after intravenous and oral administration. , 2008, Journal of drug targeting.

[11]  G. P. Martin,et al.  The controlled delivery of drugs to the lung , 1995 .

[12]  F. Xiong,et al.  Stability and pharmacokinetic studies of O-palmitoyl amylopectin anchored dipyridamole liposomes. , 2006, International journal of pharmaceutics.

[13]  C. Ji,et al.  Characterization, lung targeting profile and therapeutic efficiency of dipyridamole liposomes , 2006, Journal of drug targeting.

[14]  F. Szoka,et al.  Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[15]  N. Zhang,et al.  Preparation and evaluation of N(3)-O-toluyl-fluorouracil-loaded liposomes. , 2008, International journal of pharmaceutics.

[16]  A. Bangham,et al.  NEGATIVE STAINING OF PHOSPHOLIPIDS AND THEIR STRUCTURAL MODIFICATION BY SURFACE-ACTIVE AGENTS AS OBSERVED IN THE ELECTRON MICROSCOPE. , 1964, Journal of molecular biology.

[17]  M. Bally,et al.  Influence of pH gradients on the transbilayer transport of drugs, lipids, peptides and metal ions into large unilamellar vesicles. , 1997, Biochimica et biophysica acta.

[18]  A. Fauci,et al.  Infectious diseases: considerations for the 21st century. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  I. Kellaway,et al.  Liposomes as drug delivery systems to the lung , 1990 .

[20]  W. Couet,et al.  Formulation of rifampicin-cyclodextrin complexes for lung nebulization. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[21]  A. Scarpa,et al.  Genetic and physiological characterization of ciprofloxacin resistance in Pseudomonas aeruginosa PAO , 1988, Antimicrobial Agents and Chemotherapy.

[22]  M. Fresta,et al.  Ofloxacin-Loaded Liposomes: In Vitro Activity and Drug Accumulation in Bacteria , 2000, Antimicrobial Agents and Chemotherapy.